Skip to content
All Sections
Subscribe Now
61°F
Sunday, May 19th 2024
e-Edition
Home Page
Close Menu
News
News
Crime and Public Safety
Investigative Reporting
Politics
Health
Environment
Business
Housing
Jobs
Local News
Local News
Long Beach
Los Angeles
Los Angeles County
Sports
Sports
High School Sports
Chargers
Rams
Lakers
Clippers
Dodgers
Angels
College Sports
UCLA Sports
USC Sports
Long Beach State sports
Kings
Ducks
Boxing/MMA
Soccer
Horse Racing
Things To Do
Things To Do
Restaurants Food and Drink
Movies
Music + Concerts
Theater
TV and Streaming
Home + Garden
Travel
Amusement Parks
Comics
Puzzles
Events
Obituaries
Obituaries
News Obituaries
Place an Obituary
Opinion
Opinion
Editorials
Opinion Columns
Guest Commentary
Letters to the Editor
Editorial Board
Endorsements
The Grunion
The Grunion
News
Education
Sports
Things to Do
Opinion
E-Edition
Advertising
Contact Us
SCNG Premium
The T.E.A.
Subscribe
Press-Telegram Store
Log In
Logout
Close Menu
Get the latest news delivered daily!
Sign Up
Subscribe
Log In
Account Settings
Contact Us
Log Out
Spoof a user
Get the latest news delivered daily!
Sign Up
Subscribe
Log In
Search
Press Telegram
61°F
Sunday, May 19th 2024
e-Edition
News
Local News
Sports
Things to Do
Obituaries
Opinion
The T.E.A.
Trending:
Baseball icon Sean Burroughs dies
1 dead, 3 injured in 710 crash
Fatal Long Beach shooting
KTLA's Sam Rubin dies
ð³âðð³â⧠Pride info
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by argenx SE
< Previous
1
2
Next >
argenx Reports First Quarter 2024 Financial Results and Provides Business Update
May 09, 2024
From
argenx SE
Via
GlobeNewswire
Tickers
ARGX
argenx announces results of Annual General Meeting of Shareholders
May 07, 2024
From
argenx SE
Via
GlobeNewswire
Tickers
ARGX
argenx to Present at BofA Securities 2024 Health Care Conference
May 07, 2024
From
argenx SE
Via
GlobeNewswire
Tickers
ARGX
argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024
May 02, 2024
From
argenx SE
Via
GlobeNewswire
Tickers
ARGX
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
April 16, 2024
From
argenx SE
Via
GlobeNewswire
Tickers
ARGX
argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
March 27, 2024
From
argenx SE
Via
GlobeNewswire
Tickers
ARGX
argenx Announces Annual General Meeting of Shareholders on May 7, 2024
March 26, 2024
From
argenx SE
Via
GlobeNewswire
Tickers
ARGX
argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia
March 26, 2024
From
argenx SE
Via
GlobeNewswire
Tickers
ARGX
argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting
March 07, 2024
From
argenx SE
Via
GlobeNewswire
Tickers
ARGX
argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
February 29, 2024
From
argenx SE
Via
GlobeNewswire
Tickers
ARGX
argenx to Present at Upcoming Investor Conferences
February 26, 2024
From
argenx SE
Via
GlobeNewswire
Tickers
ARGX
argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024
February 22, 2024
From
argenx SE
Via
GlobeNewswire
Tickers
ARGX
argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy
February 20, 2024
From
argenx SE
Via
GlobeNewswire
Tickers
ARGX
argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis
January 18, 2024
From
argenx SE
Via
GlobeNewswire
Tickers
ARGX
argenx Highlights 2024 Strategic Priorities
January 08, 2024
From
argenx SE
Via
GlobeNewswire
Tickers
ARGX
argenx to Present at 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
argenx SE
Via
GlobeNewswire
Tickers
ARGX
argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus
December 20, 2023
From
argenx SE
Via
GlobeNewswire
Tickers
ARGX
argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia
November 28, 2023
From
argenx SE
Via
GlobeNewswire
Tickers
ARGX
argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Generalized Myasthenia Gravis
November 16, 2023
From
argenx SE
Via
GlobeNewswire
Tickers
ARGX
argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions
November 01, 2023
From
argenx SE
Via
GlobeNewswire
Tickers
ARGX
argenx to Present at Upcoming Investor Conferences
November 01, 2023
From
argenx SE
Via
GlobeNewswire
Tickers
ARGX
argenx Reports Third Quarter 2023 Financial Results and Provides Business Update
October 31, 2023
From
argenx SE
Via
GlobeNewswire
Tickers
ARGX
argenx to Report Third Quarter 2023 Financial Results and Business Update on October 31, 2023
October 24, 2023
From
argenx SE
Via
GlobeNewswire
Tickers
ARGX
argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis
September 21, 2023
From
argenx SE
Via
GlobeNewswire
Tickers
ARGX
argenx Announces Positive CHMP Opinion for Subcutaneous Efgartigimod for Generalized Myasthenia Gravis
September 15, 2023
From
argenx SE
Via
GlobeNewswire
Tickers
ARGX
argenx to Present at Upcoming Investor Conferences
August 30, 2023
From
argenx SE
Via
GlobeNewswire
Tickers
ARGX
argenx Reports Half Year 2023 Financial Results and Provides Second Quarter Business Update
July 27, 2023
From
argenx SE
Via
GlobeNewswire
Tickers
ARGX
argenx announces closing of global offering
July 24, 2023
From
argenx SE
Via
GlobeNewswire
Tickers
ARGX
argenx to Report Half Year 2023 Financial Results and Second Quarter Business Update on July 27, 2023
July 20, 2023
From
argenx SE
Via
GlobeNewswire
Tickers
ARGX
argenx announces full exercise of underwriters’ option to purchase additional ADSs
July 19, 2023
From
argenx SE
Via
GlobeNewswire
Tickers
ARGX
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Close